Related Experiment Video
Updated: May 27, 2025
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Behavioral Abnormalities, Cognitive Impairments, Synaptic Deficits, and Gene Replacement Therapy in a CRISPR
Jingjing Shen1, Yan Wang1, Yang Liu2
1Institute of Neuroscience, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Abstract:
The Cri du Chat Syndrome (CdCS), a devastating genetic disorder caused by a deletion on chromosome 5p, faces challenges in finding effective treatments and accurate animal models. Using CRISPR-Cas9, a novel CdCS rat model with a 2q22 deletion is developed, mirroring a common genetic alteration in CdCS patients. This model exhibits pronounced deficits in social behavior, cognition, and anxiety, accompanied by neuronal abnormalities and immune dysregulation in key brain regions such as the hippocampus and medial prefrontal cortex (mPFC). The immunostaining and RNA-seq analyses provide new insights into CdCS pathogenesis, revealing inflammatory and immune processes. Importantly, it is demonstrated that early gene replacement therapy with AAV-Ctnnd2 alleviates cognitive impairments in CdCS rats, highlighting the potential for early intervention. However, the effectiveness of this therapy is confined to the early developmental stages and does not fully restore all CdCS symptoms. The findings deepen the understanding of CdCS pathogenesis and suggest promising therapeutic directions.
Insights
A new rat model for Cri du Chat Syndrome (CdCS) shows behavioral and brain deficits. Early gene therapy offers partial cognitive improvement, suggesting potential for intervention in this genetic disorder.
Area of Science:
- Genetics
- Neuroscience
- Developmental Biology
Background:
- Cri du Chat Syndrome (CdCS) is a genetic disorder caused by a deletion on chromosome 5p.
- Developing accurate animal models and effective treatments for CdCS remains a challenge.
Purpose of the Study:
- To develop a novel rat model for CdCS using CRISPR-Cas9.
- To investigate the behavioral, neuronal, and immunological aspects of this CdCS rat model.
- To evaluate the therapeutic potential of early gene replacement therapy.
Main Methods:
- CRISPR-Cas9 gene editing to create a 2q22 deletion in rats.
- Behavioral testing for social deficits, cognition, and anxiety.
- Immunostaining and RNA-sequencing (RNA-seq) for neuronal and immune analysis.
- Adeno-associated virus (AAV)-mediated gene replacement therapy (AAV-Ctnnd2).
Main Results:
- The novel rat model successfully mimics a common CdCS genetic alteration.
- CdCS rats displayed significant social behavior, cognitive, and anxiety deficits.
- Neuronal abnormalities and immune dysregulation were observed in the hippocampus and medial prefrontal cortex (mPFC).
- Early AAV-Ctnnd2 gene therapy partially alleviated cognitive impairments.
Conclusions:
- The developed rat model provides valuable insights into CdCS pathogenesis, including inflammatory and immune processes.
- Early gene replacement therapy shows promise but has limitations in fully restoring all CdCS symptoms.
- Findings suggest potential therapeutic avenues for early intervention in CdCS.
More Related Videos
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
11:05Author Spotlight: A Battery of Highly Reproducible Behavioral Tests to Validate an Angelman Syndrome Murine Model
Published on: October 20, 2023
